Voluntarily participating in the clinical study, fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF), willingness and capability to complete all the study procedures <br/ >2. Age > 18 years at the time of signing ICF <br/ >3. Patients with laboratory confirmation of infection with SARS-CoV-2 by positive RT-PCR (within 48 hours prior to randomization) <br/ >4. Radiographic evidence of pneumonia <br/ >5. Respiratory rate > 24 breaths per minute <br/ >6. Any two of the following signs or symptoms suggestive of COVID-19: cough/shortness of breath or difficulty in breathing/fever/chills/muscle pain/sore throat/new loss of taste or smell <br/ >7. Oxygen saturation (SpO2) â?¤ 93 % on room air <br/ >8. Time interval between symptoms onset and randomization less than 10 days <br/ >9. Currently hospitalized and requiring medical care for COVID 19 <br/ >10. For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment serum pregnancy test <br/ >11. Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment, <br/ >12. Not participating in any other interventional drug clinical studies before completion of the present study. <br/ >

Voluntarily participating in the clinical study, fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF), willingness and capability to complete all the study procedures <br/ >2. Age > 18 years at the time of signing ICF <br/ >3. Patients with laboratory confirmation of infection with SARS-CoV-2 by positive RT-PCR (within 48 hours prior to randomization) <br/ >4. Radiographic evidence of pneumonia <br/ >5. Respiratory rate > 24 breaths per minute <br/ >6. Any two of the following signs or symptoms suggestive of COVID-19: cough/shortness of breath or difficulty in breathing/fever/chills/muscle pain/sore throat/new loss of taste or smell <br/ >7. Oxygen saturation (SpO2) â?¤ 93 % on room air <br/ >8. Time interval between symptoms onset and randomization less than 10 days <br/ >9. Currently hospitalized and requiring medical care for COVID 19 <br/ >10. For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment serum pregnancy test <br/ >11. Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment, <br/ >12. Not participating in any other interventional drug clinical studies before completion of the present study. <br/ >

Voluntarily participating in the clinical study, fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF), willingness and capability to complete all the study procedures <br/ >2. Age > 18 years at the time of signing ICF <br/ >3. Patients with laboratory confirmation of infection with SARS-CoV-2 by positive RT-PCR (within 48 hours prior to randomization) <br/ >4. Radiographic evidence of pneumonia <br/ >5. Respiratory rate > 24 breaths per minute <br/ >6. Any two of the following signs or symptoms suggestive of COVID-19: cough/shortness of breath or difficulty in breathing/fever/chills/muscle pain/sore throat/new loss of taste or smell <br/ >7. Oxygen saturation (SpO2) â?¤ 93 % on room air <br/ >8. Time interval between symptoms onset and randomization less than 10 days <br/ >9. Currently hospitalized and requiring medical care for COVID 19 <br/ >10. For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment serum pregnancy test <br/ >11. Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment, <br/ >12. Not participating in any other interventional drug clinical studies before completion of the present study. <br/ >

Voluntarily participating in the clinical study, fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF), willingness and capability to complete all the study procedures <br/ >2. Age > 18 years at the time of signing ICF <br/ >3. Patients with laboratory confirmation of infection with SARS-CoV-2 by positive RT-PCR (within 48 hours prior to randomization) <br/ >4. Radiographic evidence of pneumonia <br/ >5. Respiratory rate > 24 breaths per minute <br/ >6. Any two of the following signs or symptoms suggestive of COVID-19: cough/shortness of breath or difficulty in breathing/fever/chills/muscle pain/sore throat/new loss of taste or smell <br/ >7. Oxygen saturation (SpO2) â?¤ 93 % on room air <br/ >8. Time interval between symptoms onset and randomization less than 10 days <br/ >9. Currently hospitalized and requiring medical care for COVID 19 <br/ >10. For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pretreatment serum pregnancy test <br/ >11. Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment, <br/ >12. Not participating in any other interventional drug clinical studies before completion of the present study. <br/ >